Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Change in Accured Expenses (2019 - 2025)

Avidity Biosciences' Change in Accured Expenses history spans 7 years, with the latest figure at $23.7 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 366.29% year-over-year to $23.7 million; the TTM value through Dec 2025 reached $90.7 million, up 265.01%, while the annual FY2025 figure was $90.7 million, 265.01% up from the prior year.
  • Change in Accured Expenses reached $23.7 million in Q4 2025 per RNA's latest filing, down from $35.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $47.2 million in Q2 2025 to a low of -$15.3 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $7.0 million, with a median of $3.1 million recorded in 2021.
  • The largest YoY upside for Change in Accured Expenses was 2590.77% in 2024 against a maximum downside of 664.68% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.2 million in 2021, then surged by 189.19% to $6.3 million in 2022, then plummeted by 87.8% to $767000.0 in 2023, then surged by 562.97% to $5.1 million in 2024, then surged by 366.29% to $23.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Change in Accured Expenses are $23.7 million (Q4 2025), $35.1 million (Q3 2025), and $47.2 million (Q2 2025).